NFKB1 and plasma cell myeloma: This non-canonical NF-κB signaling in myeloma is in contrast to other B cell malignancies such as Waldenstrom's macroglobulinemia (lymphoplasmacytic lymphoma), where over 80% of cases harbor activating mutations in MYD88 that result in canonical NF-κB signaling (126, 127).